Greater Cannabis Company (GCAN) Receivables (2020 - 2021)
Greater Cannabis Company (GCAN) recorded quarterly Receivables of $36750.0 in Q3 2021, little changed quarter-over-quarter from $36750.0 in Q2 2021, and up 55.89% on a YoY basis from $23575.0 in Q3 2020.
Greater Cannabis Company (GCAN) Receivables (2020 - 2021) Analysis & Trends
Greater Cannabis Company's Receivables history runs 2 years deep, the most recent figure standing at $36750.0 for Q3 2021.
- In Q3 2021, Receivables rose 55.89% year-over-year to $36750.0; the TTM figure through Sep 2021 stood at $36750.0 (up 55.89% YoY), while the FY2020 annual figure was $36750.0, changed N/A from the prior year.
- Receivables was $36750.0 for Q3 2021 at Greater Cannabis Company, roughly flat from $36750.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $36750.0 in Q4 2020 to a low of $23575.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 3.39 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 1.51 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 312.00 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 31.29 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 768.10 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 1.15 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 407.63 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 355.67 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 149.62 Mn |
| 10 | Greater Cannabis Company | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 36,750.00 |
| Jun 30, 2021 | 36,750.00 |
| Mar 31, 2021 | 36,750.00 |
| Dec 31, 2020 | 36,750.00 |
| Sep 30, 2020 | 23,575.00 |
| Jun 30, 2020 | 23,575.00 |